Proxalutamide is under clinical development by Kintor Pharmaceutical and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Proxalutamide’s likelihood of approval (LoA) and phase transition for Metastatic Breast Cancer took place on 28 Jul 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Proxalutamide Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Proxalutamide overview

Proxalutamide (GT-0918) is under development for the treatment of Coronavirus COVID-19 disease, hormone senstive, castration resistant prostate cancer (CRPC) and AR positive metastatic breast cancer, HER-2 negative breast cancer and triple negative breast cancer. It is administered through oral and formulated in the form of tablet. The drug candidate acts by targeting androgen receptor.

Kintor Pharmaceutical overview

Kintor Pharmaceutical (Kintor) is a clinical stage drug company. It is involved in discovering and developing novel small molecule therapeutics targeting cancer and other androgen receptor related diseases. The company’s lead product candidate Proxalutamide (GT0918), Pyrilutamide (KX-826), ALK-1 (GT90001), Destorsertib (GT0486), GT-1798F, GT20029 and others. It offers therapeutic drugs for various disease such as metastatic castration-resistant prostate cancer, hepatocellular carcinoma, gastric carcinoma, urothelial carcinoma, Leukaemia and other disease. Kintor is involved in discovering medicine and drugs for novel diseases such as COVID -19, prostate, breast, blood and liver cancers. In addition it also carries out research and development operations to discover treatment for alopecia and acne. It carters to clients across Taiwan, Hong Kong, the Us, Brazil, and China. The company runs its operations across Hong Kong, China, and the US. Kintor is headquartered in Suzhou, Jiangsu, China.

Quick View Proxalutamide LOA Data

Report Segments
  • Innovator
Drug Name
  • Proxalutamide
Administration Pathway
  • Oral
Therapeutic Areas
  • Infectious Disease
  • Oncology
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.